Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
13.92
Nov 20 • 10:52 AM ET Dollar change+0.34 Percentage change(2.50%)
Index
RUT
Market Cap
342.23M
Enterprise Value
209.40M
Income
-255.16M
Sales
0.01M
Book/sh
7.84
Cash/sh
7.20
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
161
IPO
Jun 17, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
34222.90
P/B
1.78
P/C
1.93
P/FCF
-
EV/EBITDA
-
EV/Sales
20939.90
Quick Ratio
4.02
Current Ratio
4.02
Debt/Eq
0.23
LT Debt/Eq
0.18
Option/Short
Yes / Yes
EPS (ttm)
-11.50
EPS next Y
-6.57
EPS next Q
-1.86
EPS this Y
57.64%
EPS next Y
3.45%
EPS next 5Y
28.54%
EPS past 3/5Y
-2.70% 0.99%
Sales past 3/5Y
-92.48% -65.85%
EPS Y/Y TTM
49.87%
Sales Y/Y TTM
-63.41%
EPS Q/Q
12.38%
Sales Q/Q
-80.00%
Insider Own
63.83%
Insider Trans
41.78%
Inst Own
23.59%
Inst Trans
-1.07%
ROA
-74.85%
ROE
-97.79%
ROIC
-112.39%
Gross Margin
-59933.33%
Oper. Margin
-
Profit Margin
-
SMA20
3.75%
SMA50
25.62%
SMA200
-13.62%
Trades
Shs Outstand
24.58M
Shs Float
8.89M
52W High
45.00 -69.07%
52W Low
7.20 93.47%
Volatility
8.44% 10.41%
ATR (14)
1.27
RSI (14)
56.06
Beta
-0.21
Rel Volume
0.84
Avg Volume
174.23K
Volume
36,517
Perf Week
-2.66%
Perf Month
48.40%
Perf Quarter
-5.56%
Perf Half Y
-20.27%
Perf YTD
-54.78%
Perf Year
-20.14%
Perf 3Y
-64.12%
Perf 5Y
-93.56%
Perf 10Y
-
Prev Close
13.58
Price
13.92
Change %
2.50%
Consensus
Buy
Avg. Price Target
$37.43
Implied Upside
+168.9%
Analysts10incl. previous ratings
Rating Distribution6 Buy · 3 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 06, 2026Initiated
SF logoSStifel
Buy$36+158.6%
Jul 22, 2026Initiated
RILY logoRB. Riley Securities
Buy$44+216.1%
May 01, 2026Initiated
RRobert W. Baird
Outperform$49+252.0%
Apr 10, 2026Initiated
NNeedham
Buy$44+216.1%
Mar 09, 2026Initiated
CCitizens
Mkt Outperform$34+144.3%
Dec 09, 2025Upgrade
HH.C. Wainwright
Neutral → Buy$45+223.3%
Oct 30, 2024Downgrade
BAC logoBBofA Securities
Buy → Underperform$6 → $1-92.8%
Jun 27, 2024Downgrade
HH.C. Wainwright
Buy → Neutral$6 → $1-92.8%
Aug 28, 2023Downgrade
JPM logoJJP Morgan
Overweight → Neutral$15 → $5-64.1%
Nov 14, 2022Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight$15 → $7-49.7%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee Gary K.Chief Scientific OfficerNov 10 '26Sale15.931292,05516,091Nov 12 04:17 PM
Hill Stephen J.Chief Operating OfficerNov 10 '26Sale15.93881,40216,728Nov 12 04:16 PM
Seely LynnPresident and CEONov 10 '26Sale15.935458,68263,354Nov 12 04:14 PM
Bulis Veronica SanchezVP, Corporate ControllerNov 10 '26Sale15.934166,62714,383Nov 12 04:13 PM
ARCH Venture Partners IX, LLC10% OwnerNov 04 '26Buy10.772,321,26224,999,9923,747,790Nov 05 05:35 PM
ARCH Venture Fund XIII, L.P.10% OwnerNov 04 '26Buy10.772,321,26224,999,9923,747,790Nov 05 05:34 PM
Aguirre Jarrad MattieuChief Medical OfficerOct 12 '26Sale8.634223,64219,857Oct 13 05:17 PM
Shook DavidChief Medical OfficerSep 10 '26Sale12.705006,35020,423Sep 10 07:37 PM
Seely LynnPresident and CEOAug 21 '26Sale15.549,589149,01363,899Aug 25 04:06 PM
Hill Stephen J.Chief Operating OfficerAug 21 '26Sale15.5498915,36916,816Aug 25 04:05 PM
Lee Gary K.Chief Scientific OfficerAug 21 '26Sale15.541,45722,64216,220Aug 25 04:03 PM
Bulis Veronica SanchezVP, Corporate ControllerAug 10 '26Sale14.346218,90514,799Aug 11 04:21 PM
Lee Gary K.Chief Scientific OfficerAug 10 '26Sale14.341311,87917,677Aug 11 04:20 PM
Hill Stephen J.Chief Operating OfficerAug 10 '26Sale14.34891,27617,805Aug 11 04:18 PM
Seely LynnPresident and CEOAug 10 '26Sale14.343905,59373,488Aug 11 04:07 PM
Innovative Cellular Therapeuti10% OwnerJul 17 '26Sale13.70101372,857,480Jul 20 02:55 PM
Innovative Cellular Therapeuti10% OwnerJul 16 '26Sale13.73101372,857,490Jul 17 09:45 PM
Seely LynnPresident and CEOMay 11 '26Sale18.913887,33773,878Jun 15 06:37 PM
Lee Gary K.Chief Scientific OfficerMay 11 '26Sale18.921302,46017,808Jun 15 06:35 PM
Hill Stephen J.Chief Operating OfficerMay 11 '26Sale18.92891,68417,894Jun 15 06:34 PM
Bulis Veronica SanchezVP, Corporate ControllerMay 11 '26Sale18.912174,10315,420Jun 15 06:32 PM
Shook DavidChief Medical OfficerJun 10 '26Sale12.641,97724,98920,923Jun 11 04:07 PM
ARCH Venture Partners IX, LLC10% OwnerMar 06 '26Buy25.61488,09012,499,9851,426,528Mar 09 04:36 PM
ARCH Venture Fund XIII, L.P.10% OwnerMar 06 '26Buy25.61488,09012,499,9851,426,528Mar 09 04:34 PM
Seely LynnPresident and CEOFeb 11 '26Sale23.397,455174,37274,266Feb 12 08:47 PM
Hill Stephen J.Chief Operating OfficerFeb 11 '26Sale23.391,23628,91017,795Feb 12 08:46 PM
Lee Gary K.Chief Scientific OfficerFeb 11 '26Sale23.391,67139,08516,938Feb 12 08:44 PM
Hill Stephen J.Chief Operating OfficerFeb 10 '26Sale23.121092,52019,031Feb 11 09:05 PM
Lee Gary K.Chief Scientific OfficerFeb 10 '26Sale23.121473,39918,609Feb 11 09:04 PM
Seely LynnPresident and CEOFeb 10 '26Sale23.1243810,12781,721Feb 11 09:03 PM
Bulis Veronica SanchezVP, Corporate ControllerFeb 10 '26Sale23.122545,87215,637Feb 11 09:00 PM
Bulis Veronica SanchezVP, Corporate ControllerDec 24 '25Sale38.671,13643,9298,077Jan 06 04:02 PM
Bulis Veronica SanchezVP, Corporate ControllerDec 30 '25Sale32.3293630,2527,141Jan 06 04:02 PM
Lyell Immunopharma, Inc. operates as a holding company, which engages in the development of cell-based immunotherapies for human diseases. The company was founded by Richard D. Klausner, Stan Riddell, and Crystal Mackall in June 2018 and is headquartered in South San Francisco, CA.
Founder & Executive ChairmanDr. Richard D. Klausner M.D.
Ph.D.Dr. Lynn Seely M.D.
Chief Operating OfficerMr. Stephen J. Hill M.B.A.
Chief Scientific OfficerDr. Gary K. Lee Ph.D.
Founder & Scientific AdvisorProf. Stanley R. Riddell M.D.